Terazosin

What it is

Terazosin hydrochloride is a synthetic quinazoline alpha-1 adrenergic receptor antagonist, taken by mouth as capsules or tablets in strengths of 1, 2, 5 and 10 mg. It is almost completely absorbed, undergoes minimal first-pass metabolism so nearly all the circulating dose is the parent drug, peaks in plasma about an hour after dosing and has a half-life of roughly 12 hours, lengthening to about 14 hours in people aged 70 and over. It is one of the longer-acting, non-subtype-selective alpha-blockers, in contrast to tamsulosin and silodosin which favour the alpha-1A subtype found in the prostate.

What the research says

For urinary symptoms of an enlarged prostate the evidence is solid and the effect is symptomatic, not disease-modifying. In the 1,229-man Veterans Affairs trial, symptom scores fell 6.1 points on terazosin against 2.6 on placebo, with finasteride no better than placebo; a 17-study systematic review in 5,151 men found symptom scores improved about 38% versus 17% on placebo. It does not shrink the prostate and its own label says the long-term effect on surgery or acute retention is undetermined. For blood pressure, terazosin lowers the number but has no outcome trial of its own, and the class took a serious hit when the doxazosin arm of ALLHAT was stopped early with a doubled rate of heart failure, 8.13% against 4.45% over four years. The harms are dominated by low blood pressure on standing: dizziness in 9.1% against 4.2% on placebo, postural hypotension 3.9% against 0.8%, and documented first-dose syncope. There is also intraoperative floppy iris syndrome during cataract surgery, best quantified for tamsulosin and less well defined for terazosin.

Evidence grade: Well established.

How it works

Drug class: Selective alpha-1 adrenergic receptor antagonist (quinazoline alpha-blocker)

Noradrenaline normally keeps smooth muscle tight by acting on alpha-1 receptors. Terazosin blocks those receptors. In the prostate and at the bladder outlet that lets the muscle relax, so the urethra is squeezed less and urine flows more freely; it does not shrink the prostate. In blood vessels the same blockade widens the vessel wall, which lowers blood pressure. That second effect is why dizziness and fainting happen, particularly with the first dose, and it is the same mechanism whether the drug was prescribed for the prostate or for blood pressure. (Source 1)

What it is used for

• A 1,229-man randomised trial and a 17-study, 5,151-man systematic review both show real symptom and flow improvement over placebo, and over finasteride. The drug relieves symptoms without changing prostate size, and its long-term effect on surgery or acute urinary retention is not established. Evidence: established. (Source 2)
• Terazosin lowers blood pressure, but a Cochrane review of the whole alpha-blocker class found only 10 short trials in 1,175 people and called its own best estimate of about -8/-5 mmHg likely an overestimate. No cardiovascular outcome trial exists for terazosin. The one large outcome trial in the class, the ALLHAT doxazosin arm, was stopped early for a doubled heart failure rate. Evidence: limited. (Source 3)
• A 29-trial, 4,256-patient systematic review found alpha-blockers raised stone expulsion from 56.5% to 70.9%, a number needed to treat of 7, with a number needed to harm of 38. The network meta-analysis ranked terazosin first, though tamsulosin is the far more studied agent so the ranking rests on fewer trials. Evidence: established. (Source 4)
• In a three-arm randomised trial, terazosin alone had the lowest response rate of the three treatments, 22.4% against 45.1% for levofloxacin and 50.0% for the combination, and adding terazosin to levofloxacin made no difference. Evidence: not-supported. (Source 5)
• Two large registry cohorts found lower Parkinson incidence on terazosin-type alpha-blockers than on tamsulosin, with a dose-response pattern. A third study using matched non-users as the comparator found terazosin users no different from controls and tamsulosin users worse, which would mean the signal is tamsulosin harm rather than terazosin benefit. No randomised trial exists. Evidence: disputed. (Source 6)

Interactions

• Verapamil (pharmacokinetic study): Verapamil raises terazosin blood levels. Over three weeks of combined use terazosin exposure rose about a quarter and peak concentration a quarter, and the peak came sooner, which means more drug earlier and so more scope for a blood pressure drop. (Source 7)
• Other blood-pressure-lowering drugs: diuretics, beta-blockers and other antihypertensives (clinical trial): Blood pressure effects add up. The label found no unexpected interaction when terazosin was added to diuretics and beta-blockers in controlled trials, but it warns separately that syncope has followed the introduction of another antihypertensive drug and that additional agents should be added with caution. (Source 7)
• Phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) (clinical trial): These are co-prescribed deliberately with alpha-blockers for urinary symptoms, and 11 randomised trials in 855 men found the combination improved symptom score, flow rate and erectile function more than the alpha-blocker alone. Both drug classes lower blood pressure, so the combination is also the main setting in which additive hypotension is a concern; the trials reported it as tolerated, and terazosin's own label does not address this combination at all. Limit: The published abstract drops a minus sign. It prints the symptom-score difference as “MD: 1.66, 95% CI -3.03 to -0.29”, but a confidence interval that is entirely below zero cannot belong to a positive estimate, so the figure is -1.66. The International Prostate Symptom Score is a lower-is-better score, so as printed the number reads like a worsening when the paper is reporting an improvement of about 1.66 points. The paper is not open access, so the full text could not be checked. Read it as a small improvement in symptom score, and note that the point of this entry is the blood-pressure interaction rather than the size of the symptom benefit. (Source 8)
• Food and meals (pharmacokinetic study): Taking the capsule straight after a meal barely changes how much drug is absorbed, but it delays the peak by about 40 minutes. Since the first-dose blood pressure drop is tied to the peak, food shifts the timing of that risk rather than removing it. (Source 9)
• Saw palmetto (Serenoa repens) (clinical trial): This is the supplement most often taken for the same problem, so the question is whether it substitutes or adds. A 22-trial network meta-analysis in 8,564 men found saw palmetto gave no clinically meaningful improvement in symptoms or peak flow, while terazosin ranked highest among the active drugs. No trial has tested the two together, so there is no interaction evidence either way, only evidence that one of them works and the other does not. (Source 10)
• Aspirin, ibuprofen, indomethacin, antacids, allopurinol, antihistamines and other common co-medications (label): These were taken alongside terazosin by at least 50 patients each in the development programme without interactions being seen. The label is careful to say these were not formal interaction studies, so this is reassurance from observation rather than a tested result. (Source 7)
• Alcohol (theoretical): No interaction study exists and we found no mention of alcohol in the drug interactions section of this product's US label. The concern is mechanistic rather than measured: terazosin's main adverse effect is a fall in blood pressure on standing, alcohol is itself a vasodilator, and the label records that this orthostatic effect is greatest shortly after dosing and continues even in chronic use. That reasoning is theory, not evidence. (Source 11)
• Captopril (pharmacokinetic study): In a six-person study the two drugs did not alter each other's disposition: captopril's handling was unchanged and terazosin concentrations rose linearly with dose as expected. (Source 7)

Stopping it

• Terazosin has no withdrawal syndrome or dependence described in the literature we reached, but it does have a restart problem, which is the opposite of most tapering questions. The first-dose blood pressure drop returns if the drug is stopped for a few days, so the label treats resumption as if it were a new start and specifies going back to the initial dosing regimen. (Source 12)
• The label states the mechanism of that restart risk plainly: the same marked blood pressure fall and fainting seen with the very first dose can be expected again after an interruption of several days. (Source 13)
• Patients are told the same thing in the patient leaflet, including that the sudden drop can occur if the drug is stopped and restarted, and that a 1 mg restart may be needed. (Source 14)
• On one specific stopping question there is a clear answer: alpha-1 blockers do not need to be stopped before cataract surgery. The label states there is no apparent benefit from doing so, because the iris changes persist after the drug is withdrawn. What matters instead is that the surgeon knows the drug is being taken. (Source 15)
• Benefit stops when the drug stops. The drug relieves symptoms without altering the prostate, and the label tells patients the gland may continue to grow and that taking terazosin may not prevent the need for surgery later, so stopping returns the person to their untreated symptom level rather than to an improved baseline. (Source 1)

What goes wrong

The only large cardiovascular outcome trial of an alpha-blocker as first-line hypertension treatment doubled the four-year rate of heart failure compared with a thiazide-like diuretic, and the arm was stopped early. (Source 16)

• Randomized trial, High certainty.
• Size: 24,335 patients (9,067 doxazosin, 15,268 chlorthalidone)
• Who: Patients aged 55 or over with hypertension and at least one additional coronary heart disease risk factor, 625 centres in the US and Canada.
• How long: Median follow-up 3.3 years; planned 4-8 years, doxazosin arm discontinued on data review committee recommendation in January 2000.
• Result: Heart failure four-year rates 8.13% versus 4.45%, relative risk 2.04 (95% CI 1.79-2.32), P<.001, an absolute excess of about 3.7 percentage points or roughly 27 people treated to cause one extra heart failure event; combined cardiovascular disease 25.45% versus 21.76%, RR 1.25 (1.17-1.33); stroke RR 1.19 (1.01-1.40), P=.04; no difference in fatal coronary disease or non-fatal myocardial infarction, RR 1.03 (0.90-1.17), or in total mortality. This is doxazosin, not terazosin; the inference to terazosin is class-level.
• Funding: ALLHAT Collaborative Research Group; publicly funded trial with industry drug supply.

Considered separately, CHF risk was doubled (4-year rates, 8.13% vs 4.45%; RR, 2.04; 95% CI, 1.79-2.32; P<.001)

A dedicated validation exercise confirmed the excess heart failure in the ALLHAT doxazosin arm was real rather than a diagnostic artefact. (Source 17)

• Randomized trial, High certainty.
• Size: 105 participants with quantitative ejection fraction measurements, within the 24,335-patient trial.
• Who: ALLHAT participants with heart failure events in the doxazosin or chlorthalidone arms.
• How long: Two-year case fatality assessed.
• Result: Ejection fraction at or below 40% in 29 of 46 (63%) chlorthalidone and 41 of 59 (70%) doxazosin cases; two-year heart failure case fatality 22% versus 19%, RR 0.96 (95% CI 0.67-1.38), P=0.83; central review showed high adherence to the trial's heart failure criteria.
• Funding: ALLHAT Collaborative Research Group.

Results of the validation process supported findings of increased heart failure in the ALLHAT doxazosin treatment arm compared to the chlorthalidone treatment arm.

In the pooled placebo-controlled prostate trials, dizziness, weakness and postural hypotension were all markedly more common on terazosin than on placebo. (Source 18)

• Official position, Certainty not rated.
• Size: 636 on terazosin, 360 on placebo, pooled from six placebo-controlled trials.
• Who: Men with benign prostatic hyperplasia on 1 to 20 mg once daily.
• How long: Not stated in this section.
• Result: Reading the table's terazosin figures before the placebo figures: dizziness 9.1% versus 4.2%, somnolence 3.6% versus 1.9%, vertigo 1.4% versus 0.3%; asthenia 7.4% versus 3.3%; postural hypotension 3.9% versus 0.8%; syncope 0.6% versus 0.0%; impotence 1.6% versus 0.6%; nasal congestion/rhinitis 1.9% versus 0.0%. Urinary tract infection was less common on terazosin, 1.3% versus 3.9%.
• Funding: manufacturer label (A-S Medication Solutions), SPL published 2026-09-16.

Asthenia, postural hypotension, dizziness, somnolence, nasal congestion/rhinitis, and impotence were the only events that were significantly (p ≤ 0.05) more common in patients receiving terazosin than in patients receiving placebo.

The label's own table gives the drug-versus-placebo nervous system rates, with dizziness roughly doubled. (Source 19)

• Official position, Certainty not rated.
• Size: 636 terazosin, 360 placebo.
• Who: Men with benign prostatic hyperplasia in six placebo-controlled trials.
• How long: Not stated.
• Result: Terazosin column precedes placebo column: dizziness 9.1% versus 4.2%, somnolence 3.6% versus 1.9%, vertigo 1.4% versus 0.3%. The dagger in the table marks the comparisons at p <= 0.05, which here are dizziness and somnolence but not vertigo.
• Funding: manufacturer label (A-S Medication Solutions), SPL published 2026-09-16.

NERVOUS SYSTEM Dizziness Somnolence Vertigo 9.1% † 3.6% † 1.4% 4.2% 1.9% 0.3%

Early dose-finding work produced fainting in 3 of 14 people and blood pressure falling to 50/0 mmHg in two more, all within 90 minutes of a dose. (Source 11)

• Official position, Certainty not rated.
• Size: 14 subjects in early investigational studies.
• Who: Early investigational subjects given single doses of 2.5, 5 and 7.5 mg, above the recommended starting dose.
• How long: Single doses at 3-day intervals; effects within 90 minutes.
• Result: Syncope in 3 of 14; severe orthostatic hypotension with blood pressure falling to 50/0 mmHg in two others; dizziness, tachycardia and lightheadedness in most subjects. Tolerance to the first-dose effect did not necessarily develop.
• Funding: manufacturer label (A-S Medication Solutions), SPL published 2026-09-16.

Syncopal episodes occurred in 3 of the 14 subjects given terazosin at doses of 2.5, 5 and 7.5 mg, which are higher than the recommended initial dose; in addition, severe orthostatic hypotension (blood pressure falling to 50/0 mmHg) was seen in two others

Across nearly 2,000 hypertensive patients in multiple-dose trials, about 1% had a syncopal episode, and it was not confined to the first dose. (Source 11)

• Official position, Certainty not rated.
• Size: Nearly 2,000 hypertensive patients.
• Who: Hypertensive patients in multiple-dose clinical trials.
• How long: Not stated; risk greatest in the first seven days but continuing at all intervals.
• Result: Syncope in about 1% of patients; postural hypotension 5.1%, 5.2% and 3.7% in three placebo-controlled BPH studies.
• Funding: manufacturer label (A-S Medication Solutions), SPL published 2026-09-16.

In multiple dose clinical trials involving nearly 2000 hypertensive patients treated with terazosin capsules, syncope was reported in about 1% of patients. Syncope was not necessarily associated only with the first dose.

Symptoms of low blood pressure affected around a quarter of people in the trials: 28% in hypertension trials and 21% in prostate trials. (Source 15)

• Official position, Certainty not rated.
• Size: Clinical trial populations, sizes not given in this section.
• Who: Patients in terazosin hypertension and BPH trials.
• How long: Not stated.
• Result: Dizziness, lightheadedness or palpitations in some 28% of hypertension trial patients; 21% of BPH trial patients had one or more of dizziness, hypotension, postural hypotension, syncope or vertigo.
• Funding: manufacturer label (A-S Medication Solutions), SPL published 2026-09-16.

other symptoms of lowered blood pressure, such as dizziness, lightheadedness and palpitations, were more common and occurred in some 28% of patients in clinical trials of hypertension. In BPH clinical trials, 21% of the patients experienced one or more of the following: dizziness, hypotension, postural hypotension, syncope, and vertigo.

Priapism, which can cause permanent erectile dysfunction if untreated, has been reported with terazosin, very rarely. (Source 20)

• Official position, Certainty not rated.
• Size: Two or three dozen reported cases.
• Who: Men taking terazosin or other alpha-1 antagonists.
• How long: Not applicable.
• Result: Estimated at less than once in every several thousand patients.
• Funding: manufacturer label (A-S Medication Solutions), SPL published 2026-09-16.

Rarely, (probably less than once in every several thousand patients), terazosin and other α1-antagonists have been associated with priapism (painful penile erection, sustained for hours and unrelieved by sexual intercourse or masturbation).

Alpha-1 blockers cause intraoperative floppy iris syndrome during cataract surgery, but the quantified risk belongs to tamsulosin; terazosin's own contribution is less well characterised. (Source 21)

• Meta-analysis, Low certainty.
• Size: 38 studies in the meta-analysis.
• Who: Patients undergoing cataract surgery.
• How long: Intraoperative.
• Result: Odds ratios for predisposing to floppy iris syndrome: tamsulosin 31.06 (95% CI 13.74-70.22), antipsychotics 6.91 (2.22-21.50), finasteride 4.60 (1.97-10.73), male sex 4.25 (2.58-7.01), benzodiazepines 2.88 (1.17-7.12), hypertension 1.55 (1.01-2.37). Terazosin is not separately quantified in this analysis.
• Funding: not stated in the abstract; PRISMA-compliant systematic review and meta-analysis.

The factors that were found to predispose to IFIS significantly were male sex (odds ratio [OR], 4.25; CI, 2.58-7.01), hypertension (OR, 1.55; CI, 1.01-2.37), tamsulosin (OR, 31.06; CI, 13.74-70.22), finasteride (OR, 4.60; CI, 1.97-10.73), benzodiazepines (OR, 2.88; CI, 1.17-7.12), and antipsychotics intake (OR, 6.91; CI, 2.22-21.50).

A narrative review of the floppy iris literature states explicitly that terazosin has been linked to the syndrome but that the relationship is not as well defined as tamsulosin's. (Source 22)

• Expert review, not systematic, Very low certainty.
• Size: Literature search of PubMed, EMBASE and Web of Science to May 2021; number of included reports not stated.
• Who: Patients on alpha-1 blockers undergoing cataract surgery.
• How long: Not applicable.
• Result: No pooled estimate; a qualitative statement about strength of evidence by agent.
• Funding: not stated in the abstract.

Other adrenergic alpha-1 receptor antagonists, including terazosin, doxazosin, alfuzosin, and sildosin, have also been linked to IFIS; however, their relationship to IFIS is not as well defined.

In the same analysis adverse events from alpha-blockers were infrequent, with a number needed to harm of 38. (Source 4)

• Meta-analysis, Moderate certainty.
• Size: 29 RCTs, 4,256 patients.
• Who: Patients with ureteral stones 10 mm or smaller.
• How long: Varies by trial.
• Result: Number needed to harm 38; retrograde ejaculation most common and most associated with silodosin rather than terazosin.
• Funding: not stated in the abstract.

Adverse events were infrequent (Number Needed to Harm (NNH) = 38), with retrograde ejaculation being most common with silodosin.

Terazosin produced small but statistically significant falls in haematocrit, haemoglobin, white cells, total protein and albumin in controlled trials, suggesting haemodilution. (Source 23)

• Official position, Certainty not rated.
• Size: Controlled clinical trial populations, sizes not given.
• Who: Patients in terazosin controlled clinical trials.
• How long: Up to 24 months for the PSA observation.
• Result: Small significant decreases in haematocrit, haemoglobin, white blood cells, total protein and albumin; no significant effect on prostate specific antigen up to 24 months.
• Funding: manufacturer label (A-S Medication Solutions), SPL published 2026-09-16.

Small but statistically significant decreases in hematocrit, hemoglobin, white blood cells, total protein and albumin were observed in controlled clinical trials. These laboratory findings suggested the possibility of hemodilution.

The patient leaflet's own warning is that terazosin can drop blood pressure suddenly after the very first dose, and that the same thing can happen again after a break in treatment. (Source 24)

• Official position, Certainty not rated.
• Size: Not applicable - label text.
• Who: Anyone prescribed terazosin capsules for high blood pressure or benign prostatic hyperplasia.
• How long: Highest in the first few doses, but stated as possible at any time during treatment and again on restarting.
• Result: Dizziness, faintness or light-headedness, particularly on standing up from bed or a chair; the leaflet states treatment starts at 1 mg and is increased from there, and that the drop can recur if the drug is stopped and restarted.
• Funding: manufacturer label (A-S Medication Solutions), SPL published 2026-09-16.

Limit of this finding: This is label text, not a trial result, so it carries no rate. The trial numbers for the same effect are in the label's clinical sections: syncope in about 1% of nearly 2,000 hypertensive patients, and postural hypotension in 3.7% to 5.2% of men treated for prostate symptoms.

Terazosin Capsules Can Cause a Sudden Drop in Blood Pressure After the VERY FIRST DOSE. You may feel dizzy, faint, or “light-headed” particularly after you get up from bed or from a chair.

What the evidence supports

In a 1,229-man randomised trial, terazosin improved prostate symptom scores more than twice as much as placebo, while finasteride did no better than placebo. (Source 2)

• Randomized trial, Moderate certainty.
• Size: 1,229 men.
• Who: Men with benign prostatic hyperplasia, Veterans Affairs Cooperative Studies.
• How long: One year.
• Result: Mean symptom score fall 2.6 (placebo), 3.2 (finasteride), 6.1 (terazosin), 6.2 (combination) points, P<0.001 for terazosin and combination against finasteride and placebo. Absolute difference versus placebo about 3.5 American Urological Association points.
• Funding: Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group; funding source not stated in the abstract.

The mean changes from base line in the symptom scores in the placebo, finasteride, terazosin, and combination-therapy groups at one year were decreases of 2.6, 3.2, 6.1, and 6.2 points, respectively (P<0.001 for the comparisons of both terazosin and combination therapy with finasteride and with placebo).

Peak urinary flow improved by about 1.3 mL per second more than placebo in the same trial, and adding finasteride to terazosin added nothing. (Source 2)

• Randomized trial, Moderate certainty.
• Size: 1,229 men.
• Who: Men with benign prostatic hyperplasia.
• How long: One year.
• Result: Peak flow increases 1.4 (placebo), 1.6 (finasteride), 2.7 (terazosin), 3.2 (combination) mL per second. Discontinuation for adverse effects 1.6% on placebo versus 4.8-7.8% in the other three groups.
• Funding: VA Cooperative Studies group; funding source not stated in the abstract.

The mean changes at one year in the peak urinary-flow rates were increases of 1.4, 1.6, 2.7, and 3.2 ml per second, respectively

A systematic review of 17 trials in 5,151 men found terazosin better than placebo and finasteride and about equal to other alpha-blockers, but reported that the trials rarely allowed data pooling. (Source 25)

• Systematic review, Low certainty.
• Size: 17 studies, 5,151 men.
• Who: Men with symptomatic benign prostatic obstruction, mean age 65, 82% white, moderate symptoms at baseline.
• How long: 4 to 52 weeks.
• Result: Boyarsky symptom score improved 37% on terazosin versus 15% on placebo (four studies); AUA symptom score 38% versus 17% placebo and 20% finasteride (two studies); International Prostate Symptom Score improvement 40%, similar to tamsulosin at 43%; peak flow 22% versus 11% placebo and 15% finasteride.
• Funding: not stated in the abstract.

The pooled mean percentage improvement for the Boyarsky symptom score was 37% for terazosin and 15% for placebo (four studies).

In a network meta-analysis of symptom treatments for prostatic enlargement, terazosin ranked highest among the active drugs and saw palmetto showed no clinically meaningful benefit. (Source 10)

• Meta-analysis, Low certainty.
• Size: 22 RCTs, 8,564 patients.
• Who: Men with lower urinary tract symptoms secondary to benign prostatic enlargement.
• How long: 3 to 12 months.
• Result: Surface under the cumulative ranking curve: terazosin 99.6%, silodosin 68.5%, alfuzosin 53.7%, tamsulosin 42.3%, non-hexanic Serenoa repens 47.3%, hexanic Serenoa repens 36.7%. Ranking probabilities are not effect sizes and are sensitive to the trial network.
• Funding: not stated in the abstract; PROSPERO CRD42018084360.

Based on the surface under the cumulative ranking curve rankograms, terazosin showed the highest score (99.6%), while alfuzosin, tamsulosin, silodosin, HESr, and nHESr showed scores of 53.7%, 42.3%, 68.5%, 36.7%, and 47.3%, respectively.

Used off-label to help a ureteral stone pass, alpha-blockers raised expulsion from 56.5% to 70.9%, a number needed to treat of 7, with terazosin ranked first in the network comparison. (Source 4)

• Meta-analysis, Moderate certainty.
• Size: 29 RCTs, 4,256 patients.
• Who: Patients with ureteral stones 10 mm or smaller, trials published 2010-2025.
• How long: Varies by trial; expulsion time reduced by about three days.
• Result: Expulsion 70.9% versus 56.5%, risk ratio 1.25 (95% CI 1.20-1.32), NNT 7; distal stones RR 1.52, NNT 4; stones 5-10 mm RR 1.35, NNT 6; number needed to harm 38. The network ranking put terazosin first, but the review notes tamsulosin is the most studied agent.
• Funding: not stated in the abstract.

Alpha-blockers significantly increased stone expulsion rates compared to controls (70.9% vs. 56.5%; RR 1.25, 95% CI 1.20-1.32; Number Needed to Treat (NNT) = 7) and reduced expulsion time by approximately three-days.

Two national registry cohorts found lower Parkinson disease incidence in users of terazosin-type alpha-blockers than in users of tamsulosin, with a dose-response gradient. (Source 6)

• Cohort study, Low certainty.
• Size: 52,365 propensity-matched pairs in Denmark and 94,883 in a US claims database.
• Who: Men without Parkinson disease starting terazosin, doxazosin or alfuzosin versus tamsulosin for benign prostatic hyperplasia or unspecified urinary problems, mean age 67.9 and 63.8 years.
• How long: At least one year of follow-up; Danish data 1996-2017, US data 2001-2017.
• Result: Hazard ratio for developing Parkinson disease 0.88 (95% CI 0.81-0.98) in Denmark and 0.63 (0.58-0.69) in the US cohort, with decreasing hazard across short, medium and long duration of use (US long-duration HR 0.46, 0.36-0.57). Observational: an association in an active-comparator design, not a demonstrated effect.
• Funding: not stated in the abstract.

Limit of this finding: These two cohorts compare terazosin-type users against tamsulosin users, not against people taking nothing, so a lower rate can mean either that terazosin protects or that tamsulosin is harmful. A third cohort (sacco-2021-jci-pd) added matched non-users and found terazosin-type users no different from them, which favours the second reading. Nothing here is a trial, so none of it shows that terazosin prevents Parkinson disease.

Patients in the Danish cohort who used terazosin/doxazosin/alfuzosin had a hazard ratio (HR) for developing PD of 0.88 (95% CI, 0.81-0.98), and patients in the Truven cohort had an HR of 0.63 (95% CI, 0.58-0.69).

What the evidence does not support

A Cochrane review of the whole alpha-blocker class in hypertension found only 10 short trials and judged its own blood-pressure estimate likely to be an overestimate. (Source 3)

• Systematic review, Low certainty.
• Size: 10 trials, 1,175 participants.
• Who: Patients with primary hypertension, baseline blood pressure 155/101 mmHg, on fixed-dose alpha-blocker monotherapy versus placebo.
• How long: 3 to 12 weeks.
• Result: Best estimate of trough blood pressure lowering -8/-5 mmHg, described by the reviewers as unsatisfactory and likely an overestimate; no meaningful difference between individual alpha-blockers.
• Funding: Cochrane review; funding not stated in the abstract.

Based on the limited number of published RCTs, the BP lowering effect of alpha blockers is modest; the estimate of the magnitude of trough BP lowering of -8/-5 mmHg is likely an overestimate.

The same trial found no benefit at all for the outcome it was designed to test: fatal coronary disease or non-fatal heart attack were no different between doxazosin and the diuretic. (Source 16)

• Randomized trial, High certainty.
• Size: 24,335 patients.
• Who: High-risk hypertensive patients aged 55 and over.
• How long: Median 3.3 years.
• Result: 365 events on doxazosin and 608 on chlorthalidone; relative risk 1.03 (95% CI 0.90-1.17), P=.71. Total mortality four-year rates 9.62% versus 9.08%, RR 1.03 (0.90-1.15), P=.56.
• Funding: ALLHAT Collaborative Research Group.

A total of 365 patients in the doxazosin group and 608 in the chlorthalidone group had fatal CHD or nonfatal MI, with no difference in risk between the groups (relative risk [RR], 1.03; 95% confidence interval [CI], 0.90-1.17; P=.71).

For chronic prostatitis and chronic pelvic pain syndrome, terazosin alone performed worst of three randomised arms. (Source 5)

• Randomized trial, Low certainty.
• Size: 115 patients (38 levofloxacin, 38 terazosin, 39 combination)
• Who: Men with category III chronic prostatitis/chronic pelvic pain syndrome.
• How long: 6 weeks.
• Result: NIH-CPSI response rate 45.1% levofloxacin, 22.4% terazosin, 50.0% combination; adding terazosin to levofloxacin made no significant difference; no difference between IIIA and IIIB subtypes; erectile function scores unchanged.
• Funding: not stated in the abstract; a published commentary questioned the trial's design.

After 6 weeks, the response rate of NIH-CPSI scores was 45.1, 22.4, and 50.0 % in the levofloxacin group, terazosin group, and combination group, respectively.

A third cohort using matched non-users as well as tamsulosin found terazosin-type users no different from controls, suggesting the signal is tamsulosin harm rather than terazosin benefit. (Source 26)

• Cohort study, Low certainty.
• Size: 113,450 individuals: 45,380 tamsulosin users, 22,690 terazosin/alfuzosin/doxazosin users, 45,380 matched controls.
• Who: US individuals with 5 or more years of follow-up, matched for age, sex and Charlson comorbidity index.
• How long: 5 or more years.
• Result: Parkinson disease incidence 1.53% in tamsulosin users, 1.10% in terazosin/alfuzosin/doxazosin users (P < 0.0001 versus tamsulosin), 1.01% in matched controls; terazosin-type users did not differ from controls (P = 0.29)
• Funding: industry-funded: supported by Cerevel Therapeutics.

Limit of this finding: This cohort and the two registry cohorts in simmering-2021-jamaneurol-pd disagree, and both are observational. The disagreement is about the comparison group rather than the arithmetic: against tamsulosin users the terazosin group looks better, while against matched non-users it does not differ. The study was funded by Cerevel Therapeutics. Neither result should be read on its own.

Terazosin/alfuzosin/doxazosin users did not differ in Parkinson disease risk from matched controls (P = 0.29).

The drug's own label states its long-term effect on surgery and acute urinary obstruction is undetermined, which is a limit on the benefit claim rather than a harm. (Source 27)

• Official position, Certainty not rated.
• Size: Not applicable.
• Who: Men with symptomatic benign prostatic hyperplasia.
• How long: Not applicable.
• Result: No outcome data; approximately 70% of patients experience increased urinary flow and symptom improvement.
• Funding: manufacturer label (A-S Medication Solutions), SPL published 2026-09-16.

The long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined.

Where the evidence is mixed

The same review recorded a weakness in the evidence base: efficacy outcomes were seldom reported in a poolable form. (Source 25)

• Systematic review, Low certainty.
• Size: 17 studies, 5,151 men.
• Who: Men with symptomatic benign prostatic obstruction.
• How long: 4 to 52 weeks.
• Result: No pooled estimate possible for most outcomes; a statement about reporting quality.
• Funding: not stated in the abstract.

Efficacy outcomes were rarely reported in a way that allowed for data pooling

The same review could not estimate how often alpha-blockers cause harm, because the trials were too short and often did not report adverse effects. (Source 3)

• Systematic review, Low certainty.
• Size: 10 trials, 1,175 participants.
• Who: Primary hypertension.
• How long: 3 to 12 weeks.
• Result: No usable harm estimate.
• Funding: Cochrane review; funding not stated in the abstract.

The review did not provide a good estimate of the incidence of harms associated with alpha blockers because of the short duration of the trials and the lack of reporting of adverse effects in many of the trials.

In people already diagnosed with Parkinson disease, a Veterans Affairs cohort found fewer disease-related events on PGK1-activating alpha-blockers than on tamsulosin, and the authors called for randomised trials. (Source 28)

• Cohort study, Very low certainty.
• Size: 24,539 of 127,142 patients starting Parkinson pharmacotherapy who concurrently received an alpha-1 antagonist (14,571 PGK1-activating, 9,968 tamsulosin)
• Who: US Veterans Affairs patients initiating Parkinson-related pharmacotherapy 2000-2019.
• How long: One year of follow-up.
• Result: Incidence rate ratio for Parkinson-related events 0.80 (95% CI 0.77-0.83) unadjusted and 0.85 (0.81-0.88) adjusted. Outcomes were identified from ICD codes as clinical markers of progression, not from clinical rating scales.
• Funding: not stated in the abstract.

These results may indicate a role for terazosin and other PGK1 activators in slowing disease progression of PD; however, randomized controlled trials are needed.

Where the research disagrees

Whether terazosin-type alpha-blockers protect against Parkinson disease

• Simmering and colleagues, JAMA Neurology (2021), Propensity-matched active-comparator cohorts in Danish national registries (52,365 pairs) and a US claims database (94,883 pairs), with dose-response analyses: "These data suggest that users of terazosin/doxazosin/alfuzosin are at lower hazard of developing PD compared with users of tamsulosin. Future work is needed to further assess this association." (Source 6)
• Sacco and colleagues, Journal of Clinical Investigation (2021), Cohort of 113,450 US individuals with 5 or more years of follow-up, adding matched non-users as a third comparator; industry-funded by Cerevel Therapeutics: "These results suggest that zosins may not confer a protective effect against Parkinson disease, but rather that tamsulosin may in some way potentiate Parkinson disease progression." (Source 26)

Whether an alpha-blocker is an acceptable first-line treatment for hypertension

• ALLHAT Collaborative Research Group (2000), Randomised, double-blind, active-controlled trial in 24,335 high-risk hypertensive patients; the doxazosin arm was stopped early on data review committee advice: "Our data indicate that compared with doxazosin, chlorthalidone yields essentially equal risk of CHD death/nonfatal MI but significantly reduces the risk of combined CVD events, particularly CHF, in high-risk hypertensive patients." (Source 16)
• Heran and colleagues, Cochrane review (2012), Systematic review of 10 short placebo-controlled trials in 1,175 participants, measuring blood pressure only and not outcomes: "There are no clinically meaningful BP lowering differences between different alpha blockers." (Source 3)

How much

• Reference intake: There is no dietary reference intake for a prescription drug. Dosing is set by the prescriber. As a position, the US label (SPL published 2026-09-16) requires treatment to begin at 1 mg at bedtime, states that the 2, 5 and 10 mg capsules are not indicated as initial therapy, and gives a usual hypertension range of 1 mg to 5 mg once daily. (Source 13)
• Upper limit: As a position, the label states that 10 mg once daily is generally required for a clinical response in benign prostatic hyperplasia, that there are insufficient data to support doses above 20 mg daily in that setting, and for hypertension that doses over 20 mg do not appear to add further blood pressure effect and doses over 40 mg have not been studied. (Source 29)
• Studied: The Veterans Affairs Cooperative trial gave terazosin 10 mg daily, finasteride 5 mg daily, both, or placebo to 1,229 men for one year. (Source 2)
• Studied: The 17-trial systematic review pooled studies using terazosin at a range of doses over 4 to 52 weeks in 5,151 men. (Source 25)
• Studied: The label's pooled BPH safety data come from six placebo-controlled trials of once-daily terazosin at doses ranging from 1 to 20 mg. (Source 18)
• Studied: ALLHAT, the class outcome trial, used doxazosin 2 to 8 mg per day against chlorthalidone 12.5 to 25 mg per day in 24,335 patients; it did not test terazosin. (Source 16)

A common belief, and what the research shows

The belief: Terazosin treats the enlarged prostate, so it shrinks the gland and removes the need for surgery.

What the research shows: It does neither. It relaxes muscle in the prostate and bladder outlet so urine passes more easily, and the patient leaflet says it outright: "Terazosin Capsules help relieve the symptoms of BPH. It does NOT change the size of the prostate, which may continue to grow." The label adds that "The long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined." A second misconception is that the first-dose fainting risk is over once you have taken the drug for a while: the label records that risk is greatest in the first seven days but continues at all time intervals, and returns if the drug is stopped for several days and restarted.

Questions and answers

What is it?

Terazosin is a prescription tablet or capsule in the alpha-blocker family, given once a day. In the US it is approved for two quite different jobs: relieving the urinary symptoms of an enlarged prostate, and lowering high blood pressure. It comes in 1, 2, 5 and 10 mg strengths, and treatment always starts at 1 mg at bedtime because of the risk of fainting with the first dose. (Source 27)

What does it do in the body?

It blocks alpha-1 receptors, which are the switch noradrenaline uses to keep smooth muscle contracted. In the prostate and at the bladder opening that relaxes the muscle, so the urethra is squeezed less and urine flows better. In blood vessel walls the same blockade widens the vessels and lowers blood pressure. The blood pressure effect happens whether or not that was the reason for the prescription, which is why dizziness is the commonest problem. (Source 1)

Is it good or bad for you?

It depends entirely on which job it is doing. For prostate symptoms it works: a 1,229-man trial cut symptom scores by 6.1 points against 2.6 on placebo, and it beat finasteride. For blood pressure the picture is worse: a Cochrane review found only short trials and called its own estimate likely inflated, and when an alpha-blocker was finally tested for hard outcomes, the ALLHAT doxazosin arm was stopped early with heart failure doubled, 8.13% against 4.45% over four years. The harms in either setting are the same: dizziness in 9.1% against 4.2% on placebo, postural hypotension 3.9% against 0.8%, first-dose fainting, and floppy iris syndrome during cataract surgery. (Source 25)

How do you get more of it?

Not applicable in the usual sense: terazosin is a manufactured drug, not a nutrient, so no food, supplement or behaviour raises your level of it. The amount you have is set by the prescription. The trials that define what is known used 10 mg daily in the Veterans Affairs study and 1 to 20 mg once daily in the pooled prostate safety data, and the label requires starting at 1 mg at bedtime and increasing slowly. Dose decisions belong to the prescriber. (Source 2)

If it is harmful, what reduces it?

Stopping it is what reduces exposure, and the half-life is about 12 hours so most of a dose is gone within a couple of days, longer in people over 70 whose clearance is about a third lower. Two cautions. First, restarting after a break of several days brings back the first-dose fainting risk and the label requires going back to the starting dose. Second, the iris effect that matters in cataract surgery is not fixed by stopping: the label says there is no apparent benefit from stopping before surgery. (Source 9)

Why might someone be low in it or missing it?

Does not apply: nobody is naturally deficient in terazosin. The closest real question is why someone prescribed it might not be getting the benefit, and the literature answers that in two ways. The systematic review found adverse effects led to a two- to four-fold increase in treatment discontinuation compared with other alpha-blockers. The label adds a dosing reason: 10 mg daily is generally needed for a clinical response, and a minimum of four to six weeks at that dose may be required before judging whether it works, so people stopped at a lower dose or judged too early may be undertreated. (Source 12)

Which whole foods contain it or feed it?

None. There is no whole food that contains terazosin and nothing in the diet substitutes for it. Food matters here only as timing: taking the capsule right after a meal barely changes how much is absorbed but delays the peak by about 40 minutes. The one plant product people do take for the same problem, saw palmetto, was found in a 22-trial network meta-analysis of 8,564 men not to give clinically meaningful improvement in symptoms or flow, while terazosin ranked highest among the active drugs. (Source 9)

What happens if you do not have it?

Without it, prostate symptoms return to their untreated level; this is symptom relief, not a cure. The label's own framing is that about 70% of patients get increased urinary flow and symptom improvement on the drug, that it does not change prostate size, and that its long-term effect on surgery or acute urinary obstruction is undetermined, so going without it is not known to change the chance of needing an operation. For blood pressure, the unusual feature of this drug is that stopping it has no demonstrated downside on hard outcomes, because no outcome trial of terazosin exists and the one class outcome trial favoured a diuretic. (Source 27)

How can you test for it?

What gets measured is the effect, not the drug. For prostate symptoms the trials used a symptom questionnaire, usually the American Urological Association or International Prostate Symptom Score, plus peak urinary flow rate on uroflowmetry; the label adds that terazosin does not affect prostate specific antigen, so PSA testing remains interpretable during treatment. For blood pressure, the label advises measuring at the end of the dosing interval and again two to three hours after a dose, to check the effect lasts and is not excessive. There is no routine blood level test for terazosin. (Source 2)

References

1. A-S Medication Solutions via DailyMed (FDA label, SPL published 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Patient Package Insert, What Terazosin Capsules do to treat BPH. 2026. Read the source
2. The New England journal of medicine. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.. 1996. PMID 8684407, DOI 10.1056/nejm199608223350801. Read the source
3. The Cochrane database of systematic reviews. Blood pressure lowering efficacy of alpha blockers for primary hypertension.. 2012. PMID 22895943, DOI 10.1002/14651858.cd004643.pub3. Read the source
4. Arab journal of urology. Efficacy of alpha-blockers in medical expulsive therapy for ureteral stones: A systematic review and meta-analysis of randomized controlled trials between 2010 and 2025.. 2026. PMID 41509089, DOI 10.1080/20905998.2025.2532196. Read the source
5. International urology and nephrology. A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome.. 2016. PMID 26577998, DOI 10.1007/s11255-015-1147-1. Read the source
6. JAMA neurology. Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.. 2021. PMID 33523098, DOI 10.1001/jamaneurol.2020.5157. Read the source
7. A-S Medication Solutions via DailyMed (FDA label, SPL version 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Terazosin capsules label, Drug Interactions. 2026. Read the source
8. World journal of urology. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.. 2019. PMID 29948047, DOI 10.1007/s00345-018-2370-z. Read the source
9. A-S Medication Solutions via DailyMed (FDA label, SPL published 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Pharmacokinetics. 2026. Read the source
10. European urology focus. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials.. 2021. PMID 31952967, DOI 10.1016/j.euf.2020.01.002. Read the source
11. A-S Medication Solutions via DailyMed (FDA label, SPL published 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Warnings: first-dose studies and incidence. 2026. Read the source
12. A-S Medication Solutions via DailyMed (FDA label, SPL published 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Dosage and Administration, BPH. 2026. Read the source
13. A-S Medication Solutions via DailyMed (FDA label, SPL published 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Warnings: Syncope and First-dose Effect. 2026. Read the source
14. A-S Medication Solutions via DailyMed (FDA label, SPL published 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Patient Package Insert, How to take Terazosin Capsules. 2026. Read the source
15. A-S Medication Solutions via DailyMed (FDA label, SPL version 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Terazosin capsules label, Precautions: IFIS and Orthostatic Hypotension. 2026. Read the source
16. JAMA. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.. 2000. PMID 10789664. Read the source
17. Current controlled trials in cardiovascular medicine. Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone.. 2002. PMID 12459039, DOI 10.1186/1468-6708-3-10. Read the source
18. A-S Medication Solutions via DailyMed (FDA label, SPL version 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Terazosin capsules label, Adverse Reactions: BPH. 2026. Read the source
19. A-S Medication Solutions via DailyMed (FDA label, SPL version 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Terazosin capsules label, Table 1 adverse reactions BPH. 2026. Read the source
20. A-S Medication Solutions via DailyMed (FDA label, SPL version 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Terazosin capsules label, Warnings: Priapism. 2026. Read the source
21. Journal of cataract and refractive surgery. Factors predisposing to intraoperative floppy-iris syndrome: An up-to-date meta-analysis.. 2022. PMID 35858619, DOI 10.1097/j.jcrs.0000000000001017. Read the source
22. The Senior care pharmacist. Alpha Blocker-Associated Intraoperative Floppy Iris Syndrome.. 2022. PMID 35610768, DOI 10.4140/tcp.n.2022.227. Read the source
23. A-S Medication Solutions via DailyMed (FDA label, SPL published 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Precautions: Laboratory Tests. 2026. Read the source
24. A-S Medication Solutions via DailyMed (FDA label, SPL published 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Patient Package Insert, What you should know while taking Terazosin Capsules for hypertension or BPH (WARNINGS). 2026. Read the source
25. BJU international. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects.. 2002. PMID 11856101, DOI 10.1046/j.1464-4096.2001.01441.x. Read the source
26. The Journal of clinical investigation. Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists.. 2021. PMID 33822767, DOI 10.1172/jci145112. Read the source
27. A-S Medication Solutions via DailyMed (FDA label, SPL version 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Terazosin capsules label, Indications and Usage. 2026. Read the source
28. Journal of the American Pharmacists Association : JAPhA. The impact of alpha-1-adrenergic receptor antagonists on the progression of Parkinson disease.. 2024. PMID 38097174, DOI 10.1016/j.japh.2023.12.008. Read the source
29. A-S Medication Solutions via DailyMed (FDA label, SPL published 2026-09-16). TERAZOSIN (terazosin hydrochloride) capsules - US prescribing information - Dosage and Administration, hypertension. 2026. Read the source